Total revenue

Cost Of Materials Consumed

Purchase Of Stock-In Trade
Changes In Inventories Of FG,WIP And St
Employee Benefit Expenses
Other Expenses
Total expenes
EBITDA
Depreciation
EBIT
NOPAT
Change in WC
Depreciation
Capex
FCFF
Terminal Value
Total Cash flow
Discount Factor
PV of cash flows
Valuation in INR Cr
Valutaion in USD bn

TAX
DEBT
EQUITY (book Value)
Share Price
Out standing Share (In cr)
Equity (Market Value)
D/V
E/V
Re
Rd
Rf
Beta
MRP
WACC

Mar-18

Mar-17

4
22718.74
4775.91
3350.67
-288.02
3773.66
7158.88
18771.09
3947.65
697.15
3250.51
2151.84
300.00
697.15
900.00
1648.98
87090.59
88739.57
0.705
62579.59
63874.29
10.65

3
19928.72
4189.39
3046.06
-288.02
3430.60
6508.07
16886.10
3042.62
633.77
2408.85
1594.66
300.00
633.77
900.00
1028.43

33.80%
5990
1096
387.29
41.7
16149.92
27%
73%
10.22%
9.32%
7.5%
0.34
8.0%
9.12%

1028.43
0.770
791.43

Reinvestment Rate
ROCE
g

23%
30%
7.1%

Mar-16

Mar-15 Mar 14

2
17481.34
3674.90
2769.15
-288.02
3118.73
5916.43
15191.19
2290.15
576.15
1714.00
1134.67
300.00
576.15
900.00
510.82

1
15334.50
3223.60
2517.41
-288.02
2835.21
5378.57
13666.76
1667.74
523.78
1143.97
757.31
300.00
523.78
900.00
81.08

510.82
0.840
428.97

81.08
0.916
74.30

13451.32
2827.72
2288.55
-288.02
2577.46
4889.61
12295.32
1156.00
476.16
679.84
450.05
-2329.87
476.16
922.04
2334.04
2334.04

14%
14%
10%
0%
10%
10%
TAX
10%

10%
10%

33.80%

In INR cr.
4
Mar-18

3
Mar-17

2
Mar-16

1
Mar-15

Total revenue
27030.78 23711.21 20799.31 18245.00
Cost Of Materials Consumed
3789.00
3323.68
2915.51
2557.46
Purchase Of Stock-In Trade
896.72
815.20
741.09
673.72
Changes In Inventories Of FG,WIP A
-76.54
-76.54
-76.54
-76.54
Employee Benefit Expenses
3037.19
2761.08
2510.07
2281.88
Other Expenses
6185.69
5623.36
5112.14
4647.40
Total expenes
13832.05 12446.77 11202.27 10083.93
EBITDA
13198.73 11264.43
9597.03
8161.08
Depreciation
599.15
544.69
495.17
450.15
EBIT
12599.57 10719.75
9101.87
7710.93
NOPAT
8340.92 7096.47 6025.43 5104.63
Change in WC
-1266.22 -1266.22 -1266.22 -1266.22
Depreciation
599.15
544.69
495.17
450.15
Capex
2152
2152
2152
2152
FCFF
8054.29 6755.38 5634.82 4669.01
Terminal Value
305711.49
Total Cash flow
313765.78 6755.38 5634.82 4669.01
Discount Factor
0.6875268 0.755035 0.829172 0.910589
PV of cash flows
215722.38 5100.549 4672.239 4251.545
Valuation in INR Cr
229746.72
Valutaion in USD bn
38.291119 bn

TAX
DEBT
EQUITY (book Value)
Share Price
Out standing Share (In cr)
Equity (Market Value)

33.80%
2409.01
7407.88
625
209
130625

D/V
E/V

1.81%
98.19%

Re
Rd

9.900%
8.20%

Rf
Beta
MRP

7.50%
0.3
8%

WACC

9.82%

Reinvestment Rate
ROCE
g

3.44%
85.0%
7.0%

Mar-14
16004.39
2243.39
612.47
-76.54
2074.44
4224.91
9078.67
6925.72
409.23
6516.49
4313.92

-1266.22
409.23
2152
3837.37
3837.37

14%
14%
10%
0%
10%
10%

10%

This data can be easily copy pasted into a Microsoft Excel sheet
Ranbaxy Laboratories
Consolidated Profit & Loss account

------------------- in Rs. Cr. --------Mar 14

15 mths

INCOME
Revenue From Operations [Gross]
Less: Excise/Sevice Tax/Other Levies
Revenue From Operations [Net]
Other Operating Revenues
Total Operating Revenues
Other Income
Group Share In Joint Ventures
Total Revenue
EXPENSES
Cost Of Materials Consumed
Purchase Of Stock-In Trade
Purchase of Crude Oil And Others
Cost of Power Purchased
Cost Of Fuel
Aircraft Fuel Expenses
Aircraft Lease Rentals
Operating And Direct Expenses
Changes In Inventories Of FG,WIP And Stock-In Trade
Employee Benefit Expenses
Finance Costs
Provsions and Contingencies
Depreciation And Amortisation Expenses
Miscellaneous Expenses Written Of
Other Expenses
Less: Inter Unit / Segment / Division Transfer
Less: Transfer to / From Investment / Fixed Assets / Others
Less: Amounts Transfer To Capital Accounts
Less: Share of Loss From Partnership Firm
Group Share In Joint Ventures
Total Expenses
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax
Exceptional Items
Profit/Loss Before Tax
Tax Expenses-Continued Operations
Current Tax
Less: MAT Credit Entitlement
Deferred Tax
Other Direct Taxes
Tax For Earlier Years
Total Tax Expenses

13,084.34
44.02
13,040.32
228.16
13,268.49
182.83
0
###
2,827.72
2,288.55
0
0
0
0
0
0
-288.02
2,577.46
557.26
0
476.16
0
4,889.61
0
0
0
0
0
13,328.74
122.58
-864.33
-741.76
366.4
0
-25.58
0
-9.38
331.45

Profit/Loss After Tax And Before ExtraOrdinary Items

Prior Period Items
Extraordinary Items
Profit/Loss From Continuing Operations
Profit Loss From Discontinuing Operations
Total Tax Expenses Discontinuing Operations
Net Profit Loss From Discontinuing Operations
Profit/Loss For The Period
Minority Interest
Share Of Profit/Loss Of Associates
Consolidated Profit/Loss After MI And Associates
OTHER ADDITIONAL INFORMATION
EARNINGS PER SHARE
Basic EPS (Rs.)
Diluted EPS (Rs.)
Imported Raw Materials
Indigenous Raw Materials
Imported Stores And Spares
Indigenous Stores And Spares
DIVIDEND AND DIVIDEND PERCENTAGE
Equity Share Dividend
Preference Share Dividend
Tax On Dividend

Source :Dion Global Solutions Limited

-1,073.21
0
0
-1,073.21
0
0
0
-1,073.21
2
-14.04
-1,085.25
41.7403846154

-26
-26
0
0
0
0
0
0
0

----------------- in Rs. Cr. ------------------Dec-12

Dec-11
12 mths

12 mths

12,280.81 9,989.05
27.91
19.05
12,252.89 9,970.00
206.83
358.99
12,459.73 10,328.99
290.74
255.92
0
0
###
###
2,060.93
1,886.31
0
0
0
0
0
0
112.88
1,928.42
303.6
0
320.25
0
4,666.03
0
0
0
0
0
11,278.41
1,472.05
-227.16
1,244.89

2,299.46
1,322.01
0
0
0
0
0
0
-287.92
1,645.08
306.42
0
394.02
0
3,857.83
0
0
0
0
0
9,536.90
1,048.00
-3,734.49
-2,686.48

291.26
0
2.65
0
0
293.9

195.96
0
0.97
0
0
196.93

Total revenue
Cost Of Materials Consumed
Purchase Of Stock-In Trade
Changes In Inventories Of FG,WIP And St
Employee Benefit Expenses
Other Expenses
Total expenes
EBITDA
Depreciation
EBIT
NOPAT
Change in WC
Depreciation
Capex
FCFF
Terminal Value
Total Cash flow
Discount Factor
PV of cash flows
Valuation in INR Cr
Valutaion in USD bn

TAX
DEBT
EQUITY (book Value)
Share Price
Out standing Share (In cr)
Equity (Market Value)
D/V
E/V
Re
Rd
Rf
Beta
MRP
WACC

950.99
0
0
950.99
0
0
0
950.99
-9.64
-18.58
922.76

-2,883.42
0
0
-2,883.42
0
0
0
-2,883.42
-9.72
-6.59
-2,899.73

22
22
0
0
0
0

-69
-69
0
0
0
0

0
0
0

0.07
0
0

Reinvestment Rate
ROCE
g

Mar-18

Mar-17

Mar-16

4
22718.74
4775.91
3350.67
-288.02
3773.66
7158.88
18771.09
3947.65
697.15
3250.51
2151.84
300.00
697.15
900.00
1648.98
19787.79
21436.77
0.705
15118.99
16413.77
2.74

3
19928.72
4189.39
3046.06
-288.02
3430.60
6508.07
16886.10
3042.62
633.77
2408.85
1594.66
300.00
633.77
900.00
1028.43

2
17481.34
3674.90
2769.15
-288.02
3118.73
5916.43
15191.19
2290.15
576.15
1714.00
1134.67
300.00
576.15
900.00
510.82

1
15334.50
3223.60
2517.41
-288.02
2835.21
5378.57
13666.76
1667.74
523.78
1143.97
757.31
300.00
523.78
900.00
81.08

1028.43
0.770
791.49

510.82
0.840
428.99

81.08
0.916
74.30

33.80%
5990
1096
387.29
41.7
16149.92
27%
73%
10.22%
9.30%
7.5%
0.34
8.0%
9.12%

Mar-15 Mar 14

13451.32
2827.72
2288.55
-288.02
2577.46
4889.61
12295.32
1156.00
476.16
679.84
450.05
-2329.87
476.16
922.04
2334.04
2334.04

23%
30%
7.1%

Dec-12

Dec-11

12750.46
2060.93
1886.31
112.88
1928.42
4666.03
10654.57
2095.89
320.25
1775.64
1175.47
596.42
320.25
-1670.89
2570.19

10584.91
2299.46
1322.01
-287.92
1645.08
3857.83
8836.46
1748.45
394.02
1354.43
896.63

14%
14%
10%
0%
10%
10%
TAX
10%

10%
394.02
1765.14
-474.49

10%

13451.32
2827.72
2288.55
-288.02
2577.46
4889.61
33.80% 12295.32
1156
476.16
679.84
450.0541
-2329.87
476.16
922.04
2334.044

12750.46
2060.93
1886.31
112.88
1928.42
4666.03
10654.57
2095.89
320.25
1775.64
1175.474
596.42
320.25
-1670.89
2570.194

10584.91
2299.46
1322.01
-287.92
1645.08
3857.83
8836.46
1748.45
394.02
1354.43
896.6327
394.02
1765.14
-474.4873

5%
37%
21%
-355%
34%
5%
15%
-45%
49%
-62%
-62%
-491%
49%
-155%
-9%

20%
-10%
43%
-139%
17%
21%
21%
20%
-19%
31%
31%
#DIV/0!
-19%
-195%
-642%

This data can be easily copy pasted into a Microsoft Excel sheet
Ranbaxy Laboratories
Standalone Balance Sheet
------------------- in Rs. Cr. ------------------Mar 14
15 mths
EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital
Preference Share Capital
Total Share Capital
Revaluation Reserves
Reserves and Surplus
Total Reserves and Surplus
Money Received Against Share Warrants
Employees Stock Options
Total Shareholders Funds
Equity Share Application Money
Preference Share Application Money
Share Capital Suspense
Hybrid/Debt/Other Securities
Statutory Consumer Reserves
Special Appropriation Towards Project Cost
Service Line Contribution From Consumers
Government/Other Grants
NON-CURRENT LIABILITIES
Long Term Borrowings
Deferred Tax Liabilities [Net]
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Foreign Currency Monetary Item Translation Diference A/C
CURRENT LIABILITIES
Short Term Borrowings
Trade Payables
Other Current Liabilities
Short Term Provisions
Total Current Liabilities
Total Capital And Liabilities
ASSETS
NON-CURRENT ASSETS
Tangible Assets
Intangible Assets
Capital Work-In-Progress

211.66
0
211.66
0
884.83
884.83
0
0
1,096.49
0.5
0
0
0
0
0
0
0
2,472.19
0
371.94
131.45
2,975.59
0
3,518.88
975.19
4,349.59
188.81
9,032.46
13,105.04

1,946.05
66.09
179.18

Intangible Assets Under Development

Other Assets
Cnstruction Stores
Mining Development Expenditure
Assets Held For Sale
Fixed Assets
Non-Current Investments
Deferred Tax Assets [Net]
Long Term Loans And Advances
Other Non-Current Assets
Total Non-Current Assets
Foreign Currency Monetary Item Translation Diference A/C
CURRENT ASSETS
Current Investments
Inventories
Trade Receivables
Cash And Cash Equivalents
Short Term Loans And Advances
OtherCurrentAssets
Total Current Assets
Total Assets
OTHER ADDITIONAL INFORMATION
CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities
CIF VALUE OF IMPORTS
Raw Materials
Stores, Spares And Loose Tools
Trade/Other Goods
Capital Goods
EXPENDITURE IN FOREIGN EXCHANGE
Expenditure In Foreign Currency
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS
Dividend Remittance In Foreign Currency
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods
Other Earnings
BONUS DETAILS
Bonus Equity Share Capital
NON-CURRENT INVESTMENTS
Non-Current Investments Quoted Market Value
Non-Current Investments Unquoted Book Value
CURRENT INVESTMENTS
Current Investments Quoted Market Value
Current Investments Unquoted Book Value
-

4.45
0
0
0
0
2,195.77
4,078.99
0
1,077.99
174.11
7,526.86
0
1.9
1,695.14
1,237.47
790.57
1,273.29
579.82
5,578.18
13,105.04

1,222.20
856.7
12.34
0
45.73
1,435.68

3,662.18
1,431.71
146.85
26.61
4,048.35
1.9

WC
Change in WC
Source :Dion Global Solutions Limited

-3,454.28
-2,329.87

- in Rs. Cr. ------------------Dec-12

Dec-11
12 mths

12 mths

211.46
211
0
0
211.46
211
0
0
1,709.51 1,713.16
1,709.51 1,713.16
0
0
0
0
1,920.97 1,924.16
1.11
0.67
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,956.81
0
1,036.35
273.9
3,267.06
0

952.41
0
1,597.72
229.79
2,779.92
0

2,806.80 2,931.00
858.81
985.64
1,332.08 3,000.45
2,783.11 2,699.08
7,780.80 9,616.17
12,969.93 14,320.93

1,930.84
62.69
146.54

1,788.26
78.74
200.49

5990

13.06
0
0
0
0
2,153.12
3,128.14
0
1,010.71
21.57
6,313.54
0

8.63
0
0
0
0
2,076.12
3,408.15
0
941.23
0.09
6,425.59
0

3.03
2.65
1,731.84 1,655.23
1,435.89 3,682.82
2,834.77 1,937.95
504.15
339.98
146.71
276.71
6,656.39 7,895.34
12,969.93 14,320.93

789.63

927.85

717.98
14.58
0
47.25

759.27
13.43
0
56.08

1,402.89

4,771.25

0.01
3,785.69
165.89

5,411.48
170.04

146.85

146.85

48.38
3,026.18

60.96
3,306.19

2.05
0.98 -

2.65

-1,124.41 -1,720.83 Negative wC

596.42

This data can be easily copy pasted into a Microsoft Excel sheet
Ranbaxy Laboratories
Cash Flow

------------------- in Rs. Cr. ------------Mar 14

Dec-12
15 mths

Net Profit/Loss Before Extraordinary Items And Tax

Net CashFlow From Operating Activities
Net Cash Used In Investing Activities
Net Cash Used From Financing Activities
Foreign Exchange Gains / Losses
Adjustments on Amalgamation / Merger / Demerger / Others
Net Inc/Dec In Cash And Cash Equivalents
Cash And Cash Equivalents Begin of Year
Cash And Cash Equivalents End Of Year

Source :Dion Global Solutions Limited

-848.43
-1,217.10
922.04
717.28
-0.86
0
421.36
66.57
487.93

12 mths
-164.28
641.24
###
314.55
0.48
0
-714.62
781.19
66.57

-- in Rs. Cr. ------------------Dec-11

12 mths
-3,048.67
128.38
1,765.14
-1,275.14
0.98
0
619.36
161.83
781.19

This data can be easily copy pasted into a Microsoft Excel sheet
Sun Pharmaceutical Industries
Consolidated Profit & Loss account
Mar-14
Mar-13
12 mths
INCOME
Revenue From Operations [Gross]
16,199.51
Less: Excise/Sevice Tax/Other Levies
195.12
Revenue From Operations [Net]
16,004.39
Other Operating Revenues
75.97
Total Operating Revenues
16,080.36
Other Income
552.23
Total Revenue
16,632.59
EXPENSES
Cost Of Materials Consumed
2,243.39
Purchase Of Stock-In Trade
612.47
Changes In Inventories Of FG,WIP And Stock-76.54
Employee Benefit Expenses
2,074.44
Finance Costs
44.19
Depreciation And Amortisation Expenses
409.23
Other Expenses
4,224.91
Total Expenses
9,532.09
Profit/Loss Before Exceptional, ExtraOrdinary 7,100.50
Exceptional Items
-2,517.41
Profit/Loss Before Tax
4,583.09
Tax Expenses-Continued Operations
Current Tax
807.96
Deferred Tax
-105.79
Total Tax Expenses
702.17
Profit/Loss After Tax And Before ExtraOrdinar 3,880.92
Profit/Loss From Continuing Operations
3,880.92
Profit Loss From Discontinuing Operations
-1.92
Net Profit Loss From Discontinuing Operation
-1.92
Profit/Loss For The Period
3,879.00
Minority Interest
-737.53
Share Of Profit/Loss Of Associates
0
Consolidated Profit/Loss After MI And Associa 3,141.47
OTHER ADDITIONAL INFORMATION
EARNINGS PER SHARE
209.4313
Basic EPS (Rs.)
15
Diluted EPS (Rs.)
15
DIVIDEND AND DIVIDEND PERCENTAGE
Equity Share Dividend
310.67

12 mths

11,408.71
169.82
11,238.89
60.97
11,299.86
388.09
11,687.95
1,949.98
351.84
-228.48
1,534.53
43.16
336.17
2,795.75
6,782.95
4,905.00
-583.58
4,321.42
813.13
32.42
845.55
3,475.87
3,475.87
-6.53
-6.53
3,469.34
-486.28
0
2,983.06

29
29
517.79

Tax On Dividend

Source :Dion Global Solutions Limited

52.8

88

Total revenue
Cost Of Materials Consumed
Purchase Of Stock-In Trade
Changes In Inventories Of FG,WIP And Stock-In Tra
Employee Benefit Expenses
Other Expenses
Total expenes
EBITDA
Depreciation
EBIT
NOPAT
Change in WC
Depreciation
Capex
FCFF
Terminal Value
Total Cash flow
Discount Factor
PV of cash flows
Valuation in INR Cr
Valutaion in USD bn

TAX
DEBT
EQUITY (book Value)
Share Price
Out standing Share (In cr)
Equity (Market Value)

33.80%
2409.01
7407.88
625
209
130625

D/V
E/V

1.81%
98.19%

Re
Rd

9.900%
8.20%

Rf
Beta
MRP

7.50%
0.3
8%

WACC

9.82%

Reinvestment Rate
ROCE
g

3.44%
85.0%
7.0%

4
Mar-18

3
Mar-17

2
Mar-16

1
Mar-15

Mar-14

Mar-13

27030.78 23711.21 20799.31 18245.00 16004.39 11238.89

3789.00
3323.68
2915.51
2557.46
2243.39
1949.98
896.72
815.20
741.09
673.72
612.47
351.84
-76.54
-76.54
-76.54
-76.54
-76.54
-228.48
3037.19
2761.08
2510.07
2281.88
2074.44
1534.53
6185.69
5623.36
5112.14
4647.40
4224.91
2795.75
13832.05 12446.77 11202.27 10083.93 9078.67 6403.62
13198.73 11264.43
9597.03
8161.08
6925.72
4835.27
599.15
544.69
495.17
450.15
409.23
336.17
12599.57 10719.75
9101.87
7710.93
6516.49
4499.10
8340.92 7096.47 6025.43 5104.63 4313.92 2978.40

-1266.22 -1266.22
599.15
544.69
2152
2152
8054.29 6755.38
96651.479
104705.77 6755.38
0.6875268 0.755035
71988.022 5100.549
86012.356
14.335393 bn

Earning/EPS

-1266.22 -1266.22 -1266.22

495.17
450.15
409.23
2152
2152
2152
5634.82 4669.01 3837.37
5634.82 4669.01
0.829172 0.910589
4672.239 4251.545

3837.37

14%
14%
10%
0%
10%
10%

10%

Particulars
Core Sales
YoY growth(%)
Core EBITDA
Margin(%)
Core PAT
YoY growth(%)
Core EPS

Particulars
Core Sales
YoY growth(%)
Core EBITDA
Margin(%)
Core PAT
YoY growth(%)

Sunpharma
FY15E
FY16E
177943
19.3
72753
40.9
54360
16.2
26.2

205293
15.4
80321
39.1
61630
13.4
29.8

FY15E

Ranbaxy
FY16E

115651
-14.7
11860
10.3
3704
-26.7
8.8

Combined
FY15E

131623 14.7 15946 12 7994 115.8 18.9 -

Ranbaxy
FY15E
FY16E
FY17E
FY18E
FY19E
115651
132623
145886
160474
176522
-14.7
14.7
10
10
10
11860
15946
20424
25676
31774
10.3
12
14
16
18
3704
7994
11425
15251
19787
-26.7
115.8
42.9
33.5
29.7

Target multiple for terminal value

Terminal Value(multiple*Core PAT)
Discount Factor for 5 years @15%
PV of terminal value (INR million)
Terminal Value( USD billion)
Per share value

SOTP Valution
Particulars
SUNP's business
RBXY business
FTF opportnuties +Doxil
Total Intrinsic value

18
356166
0.497177
177077.4
2.951291
97

24XFY16E FDEPS
DCF of TV terminal value in
DCF of exclusive sales
sum of parts

615
97
58
770

Combined
FY16E
337916
15.1
96267
28.5
69624
19.9
28.9

This data can be easily copy pasted into a Microsoft Excel sheet
Sun Pharmaceutical Industries
Standalone Balance Sheet
Mar-14
12 mths
EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital
Total Share Capital
Reserves and Surplus
Total Reserves and Surplus
Total Shareholders Funds
Equity Share Application Money
Share Capital Suspense
NON-CURRENT LIABILITIES
Long Term Borrowings
Deferred Tax Liabilities [Net]
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
CURRENT LIABILITIES
Short Term Borrowings
Trade Payables
Other Current Liabilities
Short Term Provisions
Total Current Liabilities
Total Capital And Liabilities
ASSETS
NON-CURRENT ASSETS
Tangible Assets
Intangible Assets
Capital Work-In-Progress
Intangible Assets Under Development
Fixed Assets
Non-Current Investments
Long Term Loans And Advances
Other Non-Current Assets
Total Non-Current Assets
CURRENT ASSETS
Current Investments
Inventories
Trade Receivables
Cash And Cash Equivalents

Mar-13
12 mths

207.12
103.56
207.12
103.56
7,200.76 7,685.32
7,200.76 7,685.32
7,407.88 7,788.88
0
0
0
0
4.64
192.84
1.38
2,524.19
2,723.05

4.64
165.41
1.01
131.49
302.55

2,404.37
38.49
380.06
363.27
233.61
145.15
688.03
608.15
3,706.07 1,155.06
13,837.00 9,246.49

1,257.56
9.61
480.46
0
1,747.63
6,155.73
761.49
0.11
8,664.96

1,134.76
1.03
348.04
0
1,483.83
3,376.49
491.09
7.83
5,359.24

860
918.38
452.75
141.48

941.05
868.76
737.53
431.12

Short Term Loans And Advances

OtherCurrentAssets
Total Current Assets
Total Assets
OTHER ADDITIONAL INFORMATION
CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities
CIF VALUE OF IMPORTS
Raw Materials
Stores, Spares And Loose Tools
Trade/Other Goods
Capital Goods
EXPENDITURE IN FOREIGN EXCHANGE
Expenditure In Foreign Currency
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS
Dividend Remittance In Foreign Currency
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods
Other Earnings
BONUS DETAILS
Bonus Equity Share Capital
NON-CURRENT INVESTMENTS
Non-Current Investments Quoted Market Value
Non-Current Investments Unquoted Book Value
CURRENT INVESTMENTS
Current Investments Quoted Market Value
Current Investments Unquoted Book Value

Source :Dion Global Solutions Limited

309.32
849.5
2,490.11
59.29
5,172.04 3,887.25
13,837.00 9,246.49

1,816.58

1,103.41

289.47
49.38
90.08
148.94

269.2
49.86
94.44
121.76

684.99

252.4

2,271.33
45.47

1,923.80
37.72

184.37

80.82

63.97
6,094.00

66.6
3,314.76

860

941.05

Mar-12
12 mths

103.56
103.56
7,774.56
7,774.56
7,878.12
0
0
0
133.91
2.03
98.62
234.56
40.3
400.19
62.54
515.49
1,018.52
9,131.20

975.93
1.37
248.87
0
1,226.17
3,592.80
338.54
2.83
5,160.34
844.98
640.07
713.48
1,327.71

WC is requirement is dereasing
WC
1,465.97
Change in -1,266.22

DEBT

2,409.01

2,732.19
-220.15

2,952.34

390.61
54.01
3,970.86
9,131.20

781.55
289.52
34.71
66.9
90.78
154.94
1,462.82
1.77
80.82
63.27
3,531.07
12.09
832.73

This data can be easily copy pasted into a Microsoft Excel sheet
Sun Pharmaceutical Industries
Cash Flow

Previous Years
------------------- in Rs. Cr. ------------Mar 15
Mar-15
12 mths

Net Profit/Loss Before Extraordinary Items And Tax

Net CashFlow From Operating Activities
Net Cash Used In Investing Activities
Net Cash Used From Financing Activities
Foreign Exchange Gains / Losses
Adjustments on Amalgamation / Merger / Demerger / Others
Net Inc/Dec In Cash And Cash Equivalents
Cash And Cash Equivalents Begin of Year
Cash And Cash Equivalents End Of Year

Source :Dion Global Solutions Limited

12 mths

-1,558.97 -1,558.97
148.59
148.59
2,152.81 2,152.81
-2,674.09 -2,674.09
1.64
1.64
487.93
487.93
116.88
116.88
76.32
76.32
193.2
193.2

-- in Rs. Cr. ------------------Mar-14

Mar-13
12 mths
-2,801.09
-2,405.06
519.14
1,742.10
-1.67
0
-145.49
221.81
76.32

12 mths
663.03
106.48
460.54
-508.99
-4.94
0
53.09
168.72
221.81

Mar-12
12 mths
1,725.83
1,339.18
-773.69
-420.21
3.06
0
148.34
20.38
168.72